Scientists discovered that key antiviral proteins could not effectively fight the coronavirus in some patients because of a highly varied B‑cell population.
Though the COVID‑19 pandemic has largely receded, researchers continue to probe why the virus proved so lethal, claiming at least three million lives globally based on the most recent figures from the World Health Organization (WHO).
A fresh investigation into type I interferons—a collection of signaling proteins that constitute one of the body’s earliest shields against viral attacks—has revealed why this essential immune mechanism failed in individuals with severe COVID‑19.
The research determined that these crucial antiviral proteins could not adequately counter the coronavirus because affected individuals harbored a broad and varied set of B cells that specifically targeted the interferons themselves.
In a healthy state, type I interferons function as an early‑alert system, warning adjacent cells of a viral invasion and activating antiviral defenses before the pathogen can spread extensively throughout the body.
These results, appearing in the journal Cell, arise from a comprehensive examination of how harmful autoantibodies develop in patients with severe COVID‑19. The scientists focused on people who generated autoantibodies capable of neutralizing type I interferons, thereby disabling a vital element of the body’s antiviral immune response.
“The researchers found that these patients had a large and diverse population of B cells specifically programmed to recognize interferons,” said Rabih Halwani, Professor of Immunology at the University of Sharjah. “Importantly, this abnormal immune response was detectable before the patients developed life-threatening viral disease, suggesting that it was not simply a consequence of severe infection but rather a pre-existing defect that may have contributed to the patients’ vulnerability.”
Immune Failure and Severe COVID-19
The study has an international scope, bringing together scientists from universities and research institutions in France, Switzerland, Canada, Spain, Belgium, Saudi Arabia, Sweden, Denmark, Italy, the USA, Estonia, and the United Arab Emirates. These collaborators pooled their efforts in data collection, analysis, and interpretation of the outcomes.
This discovery is grounded in the phenomenon of extensive somatic hypermutation. Using patient‑derived monoclonal antibodies, the researchers combined X‑ray crystallography with AlphaFold3‑based structural analyses to examine hundreds of antibodies. Their work uncovered the remarkable breadth of the immune response, showing that these antibodies target three major B‑cell epitopes covering all principal regions of type I interferons.
According to Prof. Halwani, the study offers fresh perspectives on why and how the immune system of certain individuals with severe COVID‑19 failed to mount an effective defense against the deadly virus. The findings may help clinicians identify patients at elevated risk not only from COVID‑19, but also from other respiratory viral infections such as seasonal influenza, as well as future coronavirus pandemics. The results could also guide the development of new therapeutic approaches.
The conclusions are based on a thorough investigation of the behavior and function of B cells, the immune cells responsible for antibody production and long‑term immune memory. “We showed that these B cells had undergone a prolonged process called affinity maturation,” emphasized Prof. Halwani. “Under normal circumstances, affinity maturation improves the ability of antibodies so that they bind more strongly to invading microbes. In this case, however, the same process strengthened antibodies directed against the body’s own interferons.”
In other words, the immune system had refined and “trained” a response against one of its own essential antiviral defenses. By employing patient‑derived monoclonal antibodies, X‑ray crystallography, and computational structural analysis, the researchers were able to map in detail how these antibodies interacted with type I interferons.
“They identified three major regions, or epitopes, on the interferon molecules that were repeatedly targeted,” Prof. Halwani noted. “Collectively, these antibodies were capable of recognizing and neutralizing different type I interferons, including interferon‑α and interferon‑ω.” As a result, key components of the body’s antiviral system were compromised, he said.
Silent threat
The scientists present evidence that some individuals produce autoantibodies that mistakenly target and neutralize their protective interferons, weakening a critical component of the body’s antiviral defense. “Overall, these findings change the way we should view these autoantibodies,” Prof. Halwani emphasized. “They are not merely accidental antibodies that appear during a serious infection. Instead, they arise from an organized, mature, and persistent autoimmune B‑cell response that may exist silently before they become infected.”
This means that when an individual is subsequently exposed to a virus, these pre‑existing autoantibodies can disable the interferon alarm system at the precise moment it is most urgently needed. As a result, the virus can replicate unchecked during the early stages of infection, potentially increasing the likelihood of severe illness.
The findings are particularly significant because they may eventually help clinicians identify individuals at elevated risk before infection occurs, particularly older adults and people with underlying defects in immune tolerance.
In their conclusion, the researchers write, “These findings support a model in which a germinal‑center‑derived memory B‑cell response directed against type I IFNs is established before severe viral infection, providing a core mechanism linking T‑cell tolerance defect to pathogenic AAN‑I‑IFNs underlying severe viral diseases.”
Original Source URL: DOI: 10.1016/j.cell.2026.04.013
LEON BARKHO
University Of Sharjah
+971 50 165 4376
email us here
